Therefore, we treated a panel of melanoma cell lines that included the two main driving mutations in melanoma, BRAFV600E (A375, SK-Mel28, and WM-793 cells) and the NRASQ61R (SK-Mel2 cells) point mutations with the BRAF inhibitor PLX4032 (vemurafenib) for 1 or 24 h. Here, BRAF is linked to melanoma.